Chapter review

Fitzgerald PMHNP board review. ch17. Prescribing in the Older Adult: Doing More by Doing Less. This is drive 3 of 4. When I say Pause. Answer. wait, then I will give the answer. New section. High-risk psychotropics in older adults and monitoring. Topic. Table: Recommended Meds for Geriatric Depression. FITZGERALD CH17 — Prescribing in the Older Adult: Doing More by Doing Less. High-Yield Bottom Line. - **First-line** SSRIs for geriatric depression are **sertraline** and **escitalopram** due to low CYP450 enzyme inhibition and minimal drug interaction risks [1, 2]. - **Citalopram** is capped at a maximum dose of **20 mg daily** in adults over age 60 due to the risk of dose-dependent QTc interval prolongation and Torsades de Pointes. - **Mirtazapine** is the preferred agent when geriatric depression is accompanied by severe insomnia and unintentional weight loss, acting via histamine H1 and serotonin receptor antagonism. - **Duloxetine** is the preferred SNRI when depression co-occurs with chronic neuropathic pain or musculoskeletal pain. - **Bupropion** is ideal for geriatric depression presenting with severe fatigue, apathy, or psychomotor slowing, but is strictly contraindicated in patients with seizure disorders or active eating disorders. - **Safety alert**: SSRIs and SNRIs carry a significant risk of causing hyponatremia secondary to Syndrome of Inappropriate Antidiuretic Hormone secretion, particularly within the first **2 to 4 weeks** of initiation in older adults taking thiazide diuretics. - **Board trap**: TCAs such as **amitriptyline** and **imipramine**, as well as the SSRI **paroxetine**, should be avoided in older adults according to the Beers Criteria due to severe anticholinergic effects, sedation, orthostatic hypotension, and fall risk [2, 3]. Clinical Teaching Narrative: Recommended Meds for Geriatric Depression. Managing depression in the older adult requires balancing clinical efficacy against age-related changes in pharmacokinetics and pharmacodynamics [4, 5]. Reduced renal clearance, altered hepatic metabolism, decreased plasma protein binding, and heightened central nervous system sensitivity make drug selection critical for patient safety [5, 6]. First-Line SSRI and SNRI Selection. **First-line** antidepressant therapy in older adults begins with SSRIs that possess benign drug interaction profiles source 2. **Sertraline** and **escitalopram** represent the safest SSRIs for geriatric patients because they do not significantly inhibit cytochrome P450 enzymes such as CYP2D6 or CYP3A4 [1, 2]. This prevents dangerous elevations of co-administered cardiac, antihypertensive, or neurological medications [2, 7]. **Citalopram** is also effective, but carries a specific FDA warning in the geriatric population. Due to the risk of QTc interval prolongation and lethal ventricular arrhythmias, the maximum daily dose of citalopram for any patient older than 60 years is **20 mg daily**. When geriatric depression co-occurs with chronic pain, such as diabetic peripheral neuropathy or osteoarthritis, **duloxetine** is the preferred **first-line** SNRI. It dual-inhibits serotonin and norepinephrine reuptake, treating both depressive symptoms and somatic pain pathways without inducing significant anticholinergic side effects. Targeted Alternatives for Specific Geriatric Symptom Clusters. Geriatric depression frequently presents with vegetative or somatic features rather than classical sadness. Selecting an antidepressant that targets specific co-occurring symptoms allows clinicians to optimize polypharmacy by doing more with fewer drugs. When an older adult presents with major depression, profound anorexia, weight loss, and severe insomnia, **mirtazapine** is the drug of choice. At lower doses such as 15 mg at bedtime, mirtazapine exhibits strong H1 histamine receptor blockade, promoting sleep and stimulating appetite. As the dose is titrated upward to 30 mg or 45 mg daily, noradrenergic neurotransmission increases, enhancing antidepressant activity while decreasing sedating properties. When depression presents with profound psychomotor slowing, apathy, severe fatigue, or executive dysfunction, **bupropion** is the preferred activating agent. Bupropion inhibits dopamine and norepinephrine reuptake, boosting motivation and energy without causing sexual dysfunction or sedation. However, bupropion must never be prescribed to patients with an active seizure disorder or a history of bulimia or anorexia nervosa. High-Risk Antidepressants to Avoid. According to the American Geriatrics Society Beers Criteria, several traditional psychotropics carry unacceptable risks for older adults. **Safety alert**: Tricyclic antidepressants, specifically tertiary amines like **amitriptyline**, **imipramine**, and **doxepin** at doses exceeding 6 mg daily, must be avoided in older adults. These agents possess potent anticholinergic activity, blocking muscarinic receptors and causing confusion, memory impairment, delirium, dry mouth, severe constipation, urinary retention, and blurred vision. Furthermore, alpha-1 adrenergic blockade causes orthostatic hypotension and falls, while sodium channel blockade risks lethal cardiac conduction delays. Among the SSRIs, **paroxetine** is considered high-risk in older adults due to its significant anticholinergic activity and potent CYP2D6 inhibition [2, 3]. **Fluoxetine** is also problematic in geriatric prescribing because of its extremely long elimination half-life and active metabolite, which can persist for weeks and interact with co-administered medications [1, 2]. Critical Safety Alerts and Monitoring Parameters. **Safety alert**: SSRI-induced hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone secretion occur at significantly higher rates in geriatric patients. Clinicians should obtain a baseline serum sodium level prior to starting an SSRI or SNRI and recheck serum sodium within **2 to 4 weeks** after initiation, especially in patients taking concomitant thiazide diuretics or systemic corticosteroids. **Board trap**: Do not mistake SSRI-induced hyponatremia in an older adult for worsening dementia or new-onset delirium. A sudden presentation of lethargy, confusion, weakness, or gait instability shortly after initiating an antidepressant requires an immediate basic metabolic panel to evaluate serum sodium. When initiating any recommended antidepressant in an older adult, adhere to the foundational geriatric principle: start low, go slow, but titrate to full therapeutic doses. Leaving a patient on a subtherapeutic dose out of excessive caution leads to treatment failure and pseudo-resistance. Sample Board-Style Exam Questions. Question 1. An 74-year-old woman with major depressive disorder presents to the outpatient clinic accompanied by her daughter. The daughter reports that over the past 4 months, her mother has experienced persistent depressed mood, severe difficulty falling asleep, and an unintentional 12-pound weight loss. She has no history of seizures or cardiac disease. Which antidepressant medication is most appropriate for this patient? A. Fluoxetine B. Mirtazapine C. Amitriptyline D. Paroxetine Pause. Answer: B. Why it is correct: **Mirtazapine** is the most appropriate choice because its mechanism of action includes H1 histamine blockade and 5-HT2/5-HT3 antagonism, which effectively stimulates appetite and promotes sleep while treating depressive symptoms. Why the other choices are wrong: - **A:** **Fluoxetine** has a very long elimination half-life and potent CYP2D6 inhibition, making it prone to drug accumulation and interaction in older adults [1, 2]. - **C:** **Amitriptyline** is a tertiary amine tricyclic antidepressant listed on the Beers Criteria as high risk due to severe anticholinergic toxicity, orthostatic hypotension, and fall risk. - **D:** **Paroxetine** is the most anticholinergic SSRI and is associated with sedation, memory impairment, and CYP2D6 inhibition in geriatric patients [2, 3]. Test-taking pearl: Match the side-effect profile of the antidepressant to the patient's specific symptom cluster. In an older adult with depression, insomnia, and weight loss, mirtazapine solves three clinical problems with one drug. Concept tested: Geriatric antidepressant selection for depression with anorexia and insomnia. Question 2. An 67-year-old male with stable major depressive disorder is being evaluated for a medication adjustment. He has a history of hypertension and mild cognitive impairment. His current regimen includes citalopram 40 mg daily. Which clinical action should the PMHNP take regarding his antidepressant therapy? A. Increase citalopram to 60 mg daily to achieve full remission. B. Reduce citalopram to 20 mg daily due to QTc prolongation risk. C. Switch citalopram to amitriptyline 50 mg at bedtime. D. Discontinue citalopram abruptly and initiate fluoxetine 20 mg daily. Pause. Answer: B. Why it is correct: The FDA safety warning mandates that **citalopram** must not exceed **20 mg daily** in patients over 60 years of age due to the risk of dose-dependent QTc interval prolongation and Torsades de Pointes. Why the other choices are wrong: - **A:** Increasing citalopram to 60 mg daily significantly exceeds safe dosage limits and elevates the risk of fatal cardiac arrhythmias. - **C:** **Amitriptyline** is inappropriate for an older adult with cognitive impairment due to its severe anticholinergic side effects which worsen memory and increase fall risk. - **D:** Abruptly discontinuing citalopram can trigger antidepressant discontinuation syndrome, and switching to **fluoxetine** introduces long half-life drug interaction hazards [1, 2]. Test-taking pearl: Memorize age-based dosing caps. Citalopram is capped at 20 mg daily for anyone older than 60 years. Concept tested: FDA safety warnings and QTc prolongation risk with citalopram in older adults. Question 3. An 82-year-old female is started on sertraline 25 mg daily for major depressive disorder. Three weeks after starting the medication, her family brings her to the clinic because she has become acutely lethargic, confused, and unsteady on her feet. Serum laboratory testing reveals a serum sodium level of 122 mEq/L. Which underlying condition best explains her clinical presentation? A. Anticholinergic delirium B. SSRI-induced hyponatremia secondary to SIADH C. Serotonin syndrome D. Acute vascular dementia Pause. Answer: B. Why it is correct: SSRIs can cause Syndrome of Inappropriate Antidiuretic Hormone secretion leading to severe hyponatremia, particularly in older adults within the first 2 to 4 weeks of treatment. Why the other choices are wrong: - **A:** **Sertraline** does not possess significant anticholinergic activity, making anticholinergic delirium unlikely. - **C:** Serotonin syndrome presents with autonomic instability, hyperreflexia, clonus, and agitation, rather than isolated hyponatremia and lethargy. - **D:** Vascular dementia causes a stepwise cognitive decline over time rather than acute confusion and hyponatremia following drug initiation. Test-taking pearl: New-onset confusion or falls shortly after starting an SSRI in an older adult is hyponatremia secondary to SIADH until proven otherwise. Check sodium levels. Concept tested: SSRI safety monitoring and SIADH-induced hyponatremia in geriatric patients. Question 4. An 70-year-old man with major depressive disorder and painful diabetic peripheral neuropathy in his lower extremities requires antidepressant therapy. He has no history of renal impairment or urinary retention. Which medication is the most appropriate first-line choice? A. Duloxetine B. Imipramine C. Bupropion D. Diphenhydramine Pause. Answer: A. Why it is correct: **Duloxetine** is an SNRI FDA-approved for both major depressive disorder and diabetic peripheral neuropathic pain, making it the ideal dual-mechanism agent for this patient. Why the other choices are wrong: - **B:** **Imipramine** treats neuropathic pain but is a tertiary amine TCA with severe anticholinergic and cardiotoxic risks in older adults. - **C:** **Bupropion** is an effective activating antidepressant but does not possess efficacy in treating neuropathic pain. - **D:** **Diphenhydramine** is a highly anticholinergic antihistamine with no antidepressant properties and is listed on the Beers Criteria as inappropriate for older adults. Test-taking pearl: Look for dual-indication choices. SNRIs like duloxetine address both mood symptoms and neuropathic pain in geriatric patients without TCA toxicity. Concept tested: Dual-indication psychopharmacology in geriatric pain and depression. Next Study Step. Review **Fitzgerald Chapter 14: Neurocognitive Disorders and Delirium in Older Adults**, focusing on distinguishing the classic clinical triad of depression, dementia, and delirium, alongside non-pharmacological behavioral management strategies and cholinesterase inhibitor safety rules. 💡 *Would you like to generate a practice set of flashcards or a quiz focusing specifically on geriatric psychopharmacology and Beers Criteria rules?* Next. New section. Prescribing cascades, interactions, and dangerous-to-miss safety alerts. Topic. CYP2D6 Inhibition: Fluoxetine and Paroxetine. Bottom Line Summary. - **CYP2D6 Potent Inhibitors**: **Fluoxetine** and **paroxetine** are potent inhibitors of the cytochrome P450 2D6 isoenzyme and should generally be avoided in older adults on multi-drug regimens [1, 2]. - **Cardiovascular Risk**: Inhibiting **CYP2D6** blocks the clearance of substrate beta-blockers like **metoprolol**, **propranolol**, and **carvedilol**, leading to toxic drug accumulation, severe **bradycardia**, heart block, hypotension, and falls [3, 4]. - **Tricyclic Toxicity**: Co-administering **fluoxetine** or **paroxetine** with tricyclic antidepressants such as **nortriptyline** or **desipramine** increases TCA blood concentrations, risking QTc prolongation, fatal cardiac arrhythmias, and seizures [2, 5]. - **Analgesic Failure**: **CYP2D6** inhibition prevents the metabolic conversion of prodrugs like **codeine** and **tramadol** into their active analgesic metabolites, resulting in complete therapeutic failure for pain management [1, 6]. - **Dosing Thresholds in Geriatrics**: Age-related reduction in hepatic volume and blood flow decreases drug clearance; **fluoxetine** has a long active metabolite half-life of 1 to 2 weeks, extending interaction risks long after discontinuation [2, 7]. - **First-Line Alternatives**: In older adults requiring an SSRI, select agents with minimal CYP enzyme inhibition, specifically **sertraline**, **escitalopram** (maximum 10 mg daily in elderly), or **citalopram** (maximum 20 mg daily in elderly) [1, 8]. Clinical Teaching: CYP2D6 Inhibition in Geriatric Practice. Pharmacokinetic Mechanism and Hepatic Clearance. Cytochrome P450 2D6 is a primary hepatic isoenzyme responsible for metabolizing approximately 25 percent of clinically used drugs source 1. **Fluoxetine** and **paroxetine** bind strongly to the active site of the **CYP2D6** enzyme, acting as potent competitive and mechanism-based inhibitors [1, 2]. In older adults, age-related physiologic changes already impair hepatic drug clearance due to decreased liver mass and reduced hepatic blood flow source 7. When a potent **CYP2D6** inhibitor is introduced to an older patient taking co-administered substrate medications, hepatic clearance of those substrates drops precipitously, resulting in elevated serum drug concentrations and systemic toxicity [2, 3]. Prescribing Cascades and Dangerous Drug Interactions. A prescribing cascade occurs when an adverse drug reaction caused by a medication interaction is misdiagnosed as a new medical condition, prompting the initiation of an additional, unnecessary medication source 3. - **Beta-Blocker Interaction**: Beta-blockers such as **metoprolol**, **propranolol**, and **carvedilol** are extensive **CYP2D6** substrates [3, 4]. Adding **paroxetine** or **fluoxetine** inhibits **metoprolol** metabolism, causing serum levels to rise up to fourfold source 4. This manifests clinically as severe **bradycardia**, syncope, and orthostatic hypotension [3, 4]. In a classic prescribing cascade, a clinician might mistake this drug-induced bradycardia for sick sinus syndrome or worsening heart disease and inappropriately insert a pacemaker or add cardiac agents source 3. - **Tricyclic Antidepressant Toxicity**: Secondary amines like **nortriptyline** and **desipramine** rely heavily on **CYP2D6** for hydroxylation source 2. **Fluoxetine** or **paroxetine** co-administration raises TCA plasma levels into the toxic range, precipitating anticholinergic delirium, severe confusion, urinary retention, QTc prolongation, Torsades de Pointes, and seizures [2, 5]. - **Prodrug Activation Failure**: Prodrugs such as **codeine** and **tramadol** require **CYP2D6** O-demethylation to convert into their active forms, morphine and O-desmethyltramadol, respectively source 6. Inhibiting **CYP2D6** prevents this bioactivation, rendering these analgesics completely ineffective for pain control [1, 6]. - **Antipsychotic Elevation**: Substrates like **haloperidol**, **risperidone**, and **aripiprazole** undergo **CYP2D6** metabolism source 1. Co-prescribing **fluoxetine** or **paroxetine** increases antipsychotic levels, heightening the risk of extrapyramidal symptoms, parkinsonism, tardive dyskinesia, and hyperprolactinemia [1, 2]. Clinical Signposts for Board Mastery. - **Safety Alert**: Always perform a comprehensive medication reconciliation before initiating **fluoxetine** or **paroxetine** [1, 3]. Check for **CYP2D6** substrates, particularly cardiovascular medications and TCAs [3, 4]. Due to the extended half-life of **fluoxetine** and its active metabolite **norfluoxetine** (7 to 15 days), **CYP2D6** inhibition persists for several weeks after stopping the medication [2, 7]. - **Board Trap**: Board questions often present an older adult taking **metoprolol** who develops new-onset **bradycardia**, fatigue, and dizziness after starting a new antidepressant [3, 4]. The distractor choice will suggest a cardiology consult, pacemaker evaluation, or adding a stimulant source 3. The correct action is recognizing the **CYP2D6** interaction and discontinuing the offending SSRI [1, 3]. - **First-Line**: For geriatric depression or anxiety, **sertraline**, **escitalopram**, or **citalopram** represent first-line SSRI choices because they possess minimal CYP450 enzyme inhibition profiles [1, 8]. Always observe elderly dosing caps: **citalopram** is capped at 20 mg daily and **escitalopram** is capped at 10 mg daily due to dose-dependent QTc prolongation risks source 8. Comparing SSRI Isoenzyme Profiles in Older Adults. When evaluating SSRI options for geriatric patients on multi-drug regimens, compare their metabolic impact: - **Fluoxetine and Paroxetine**: Potent **CYP2D6** inhibitors [1, 2]. High risk for polypharmacy interactions, **bradycardia** with beta-blockers, and toxicity with TCAs [3, 5]. **Paroxetine** also carries strong anticholinergic properties, sedating effects, and severe discontinuation syndrome source 2. Both should generally be avoided in older adults [1, 3]. - **Sertraline, Escitalopram, and Citalopram**: Minimal to mild **CYP2D6** and CYP3A4 inhibition [1, 8]. Low potential for pharmacokinetic drug interactions, making them the preferred first-line choices for older adults [1, 8]. Board Practice Questions. Question 1. A 72-year-old male with a history of hypertension and stable coronary artery disease managed with **metoprolol** 50 mg twice daily presents with major depressive disorder [3, 4]. The PMHNP evaluates medication options source 1. Which antidepressant should be avoided due to potent **CYP2D6** inhibition and the risk of severe **bradycardia** [3, 4]? A) **Sertraline** B) **Escitalopram** C) **Paroxetine** D) **Vilazodone** Quick Answer. **Paroxetine** should be avoided because it potently inhibits **CYP2D6**, increasing **metoprolol** levels and risking severe **bradycardia** [3, 4]. Key Clue. The combination of **metoprolol** in an older adult and the need to avoid potent **CYP2D6** inhibition [3, 4]. Best Answer. C) **Paroxetine** Why It Is Correct. **Paroxetine** is a potent inhibitor of the **CYP2D6** isoenzyme [1, 2]. **Metoprolol** is metabolized primarily by **CYP2D6** source 4. Co-administering **paroxetine** impairs **metoprolol** clearance, causing blood levels to rise significantly and leading to profound **bradycardia**, hypotension, and potential syncope or falls in an older adult [3, 4]. Why the Other Choices Are Wrong. - A) **Sertraline** exhibits minimal CYP enzyme inhibition at lower doses and is a preferred first-line antidepressant in older adults with cardiovascular comorbidities [1, 8]. - B) **Escitalopram** has negligible CYP enzyme inhibition and does not significantly alter **metoprolol** metabolism [1, 8]. - D) **Vilazodone** does not potently inhibit **CYP2D6** and does not carry the same high risk of beta-blocker interaction source 1. Test-Taking Pearl. When a stem mentions an older adult on a beta-blocker or TCA, avoid choosing **fluoxetine** or **paroxetine** due to dangerous **CYP2D6** inhibition [1, 3]. Concept tested: **CYP2D6** inhibition and geriatric prescribing safety. Question 2. A 69-year-old female taking **fluoxetine** 20 mg daily for major depressive disorder is prescribed **codeine** with acetaminophen by her primary care provider following a dental procedure [1, 6]. Three days later, she reports no pain relief despite taking the medication as directed source 6. What is the physiological mechanism underlying this lack of analgesic effect [1, 6]? A) **Fluoxetine** accelerates renal elimination of **codeine** B) **Fluoxetine** inhibits **CYP2D6**, preventing conversion of **codeine** to morphine C) **Fluoxetine** competes for opioid mu-receptors in the central nervous system D) **Fluoxetine** induces CYP3A4, rapidly inactivating **codeine** Quick Answer. **Fluoxetine** inhibits **CYP2D6**, blocking the conversion of **codeine** into its active metabolite, morphine [1, 6]. Key Clue. Lack of pain relief from **codeine** in a patient taking **fluoxetine** [1, 6]. Best Answer. B) **Fluoxetine** inhibits **CYP2D6**, preventing conversion of **codeine** to morphine Why It Is Correct. **Codeine** is a prodrug that requires bioactivation into morphine via the **CYP2D6** pathway to exert its analgesic effect source 6. **Fluoxetine** is a potent **CYP2D6** inhibitor [1, 2]. Inhibiting this enzyme blocks the metabolic conversion, leaving the patient with inadequate pain relief [1, 6]. Why the Other Choices Are Wrong. - A) **Fluoxetine** does not alter renal clearance mechanisms for opioid medications [2, 7]. - C) **Fluoxetine** acts on serotonin reuptake transporters, not mu-opioid receptors source 2. - D) **Fluoxetine** is an inhibitor of **CYP2D6**, not a CYP3A4 inducer [1, 2]. Test-Taking Pearl. Prodrugs like **codeine** and **tramadol** require functional **CYP2D6** to work source 6. **CYP2D6** inhibitors like **fluoxetine** and **paroxetine** cause treatment failure for pain [1, 6]. Concept tested: **CYP2D6** prodrug interaction and bioactivation. 💡 **Next Study Step**: Review **Beers Criteria and START/STOPP Screening Tools** in geriatric prescribing to reinforce high-risk psychotropic avoidance and deprescribing protocols in older adults. Next. Topic. Anticholinergic Toxicity and Cognitive Impairment. Bottom Line Summary. * **Prescribing Cascade Definition**: A prescribing cascade occurs when an adverse drug reaction caused by one medication is misdiagnosed as a new medical condition, leading to the prescription of a second medication to treat the side effect. * **Anticholinergic Cognitive Burden**: Medications with high anticholinergic activity impair central M1 muscarinic receptors, causing acute delirium, memory loss, confusion, and accelerated cognitive decline in older adults. * **Beers Criteria High-Risk Drugs**: Avoid high-anticholinergic agents in adults 65 years and older, including first-generation antihistamines like **diphenhydramine** and **hydroxyzine**, tricyclic antidepressants like **amitriptyline** and **doxepin** above 6 mg daily, urological antispasmodics like **oxybutynin**, and antiparkinsonian agents like **benztropine**. * **The Anticholinergic-Cholinesterase Inhibitor Cascade**: Prescribing a cholinesterase inhibitor like **donepezil** to treat cognitive loss caused by **diphenhydramine** or **amitriptyline** is a classic board-tested prescribing cascade that opposes therapeutic mechanisms. * **The Urinary Incontinence Cascade**: Cholinesterase inhibitors increase acetylcholine levels and frequently cause bladder hyperreactivity and urinary incontinence, which is often misdiagnosed and inappropriately treated with **oxybutynin**, worsening central cognitive impairment. * **Deprescribing Protocol**: The priority management for medication-induced cognitive decline is step-wise deprescribing, tapering the offending anticholinergic drug, and re-evaluating baseline cognition after clearance. High-Yield Concept Review. Anticholinergic Toxicity and Central Muscarinic Blockade. Central cholinergic transmission through M1 muscarinic receptors in the hippocampus and cerebral cortex is essential for memory formation, attention, and executive function. Aging is accompanied by a physiological decline in central cholinergic reserves, increased blood-brain barrier permeability, and decreased hepatic and renal clearance. When older adults take medications with anticholinergic properties, central cholinergic blockade leads to acute confusion, short-term memory deficits, disorientation, hallucinations, and delirium. **Safety Alert**: Peripheral signs of anticholinergic toxicity include dry mouth, blurred vision, constipation, urinary retention, tachycardia, and anhidrosis. However, central cognitive impairment can occur without severe peripheral signs. In older adults, central anticholinergic toxicity frequently presents as subtle memory loss, lethargy, or executive dysfunction that mimics major neurocognitive disorder. Prescribing Cascades in Geriatric Practice. Prescribing cascades represent a major threat to safety in geriatric psychopharmacology. They begin when an unrecognized adverse drug effect is interpreted as a new disease state. **Board Trap**: Test writers frequently present an older adult taking an over-the-counter sleep aid containing **diphenhydramine** or a tricyclic antidepressant like **amitriptyline** who develops progressive memory loss. The trap option is to diagnose early Alzheimer disease and initiate **donepezil** or **galantamine**. The correct board action is to identify the anticholinergic drug as the root cause, discontinue the agent, and reassess cognitive function. A second classic prescribing cascade involves bladder medications and cognitive enhancers: 1. Patient takes **donepezil** for mild cognitive impairment or Alzheimer disease. 2. Elevated peripheral acetylcholine causes detrusor muscle contraction, resulting in new-onset urinary incontinence. 3. Provider misinterprets incontinence as age-related detrusor instability and prescribes **oxybutynin**. 4. **Oxybutynin** crosses the blood-brain barrier, antagonizes central cholinergic receptors, neutralizes the therapeutic effect of **donepezil**, and triggers acute delirium or rapid cognitive decline. **First-line**: When an older adult presents with new cognitive symptoms, urinary retention, or behavioral changes, the first-line intervention is always a comprehensive medication reconciliation to identify and deprescribe anticholinergic agents before adding any new medication or primary psychiatric diagnosis. Compare and Distinguish. Central Anticholinergic Toxicity. * **Think**: Central nervous system cholinergic blockade in the brain. * **Priority**: Immediate risk for acute delirium, confusion, memory failure, and falls. * **Key Clues**: Disorientation, hallucinations, impaired recall, executive dysfunction, lethargy. * **Boards are Testing**: Recognizing that central cognitive impairment can occur even when peripheral signs are mild or absent. Peripheral Anticholinergic Side Effects. * **Think**: Peripheral muscarinic receptor blockade in body tissues. * **Priority**: Physical discomfort, bowel obstruction, and urinary tract complications. * **Key Clues**: Dry mouth, blurred vision, constipation, urinary retention, sinus tachycardia, anhidrosis. * **Boards are Testing**: Differentiating physical anticholinergic side effects from primary medical conditions like benign prostatic hyperplasia or constipation. Prescribing Cascade. * **Think**: Adverse drug reaction misdiagnosed as a new clinical condition. * **Priority**: Harm reduction through medication reduction and elimination. * **Key Clues**: Onset of new physical or cognitive symptoms shortly after starting or titrating a medication. * **Boards are Testing**: Identifying the root cause medication and deprescribing rather than adding a second drug to treat the side effect. Primary Neurocognitive Disorder (Dementia). * **Think**: Progressive, neurodegenerative decline in cognitive domains over months to years. * **Priority**: Accurate longitudinal assessment, safety planning, and evidence-based disease management. * **Key Clues**: Gradual onset, insidious progression, absence of acute medication triggers or fluctuating delirium. * **Boards are Testing**: Ruling out reversible medication-induced causes before establishing a primary dementia diagnosis. Board-Style Practice Questions. Question 1. A 74-year-old woman is brought to the outpatient psychiatric clinic by her daughter due to a 3-month history of worsening confusion, severe short-term memory loss, and dry mouth. The daughter reports her mother was living independently until recent sleep problems developed, for which she began taking over-the-counter **diphenhydramine** 50 mg every night. The patient's physical examination is unremarkable except for dry mucous membranes and mild sinus tachycardia. Her Mini-Mental State Examination score is 22 out of 30. Which of the following is the most appropriate initial action by the psychiatric-mental health nurse practitioner? A) Initiate **donepezil** 5 mg daily for probable early-stage Alzheimer disease. B) Discontinue **diphenhydramine** and reassess cognitive status in 2 to 4 weeks. C) Order a non-contrast head CT scan and prescribe **galantamine**. D) Switch **diphenhydramine** to **amitriptyline** 25 mg at bedtime for sleep and mood. Pause. Answer: B **Why It Is Correct**: The patient is experiencing central and peripheral anticholinergic toxicity secondary to daily **diphenhydramine** use. First-generation antihistamines possess potent anticholinergic activity that crosses the blood-brain barrier, causing memory impairment, confusion, and delirium in older adults. The most appropriate initial action is to discontinue the offending anticholinergic agent and allow time for drug clearance before evaluating for a primary neurocognitive disorder. **Why the Other Choices Are Wrong**: * **A**: Initiating **donepezil** represents a classic prescribing cascade where a drug-induced cognitive side effect is misdiagnosed as primary dementia and treated with an opposing cholinergic agent. * **C**: Ordering imaging and prescribing a second cholinesterase inhibitor is inappropriate before eliminating the clear anticholinergic cause of cognitive impairment. * **D**: **Amitriptyline** is a tricyclic antidepressant with extremely high anticholinergic activity that would severely exacerbate her cognitive decline, tachycardia, and dry mouth. **Test-Taking Pearl**: Always eliminate over-the-counter anticholinergic medications before evaluating or treating cognitive impairment in an older adult. Question 2. An 80-year-old male with mild Alzheimer disease has been stabilized on **donepezil** 10 mg daily for 1 year with stable cognitive scores. Two months ago, he developed new-onset urinary incontinence and was started on **oxybutynin** 5 mg twice daily by his primary care provider. Today, his wife reports that over the past 6 weeks he has become acutely disoriented, agitation has increased, and he can no longer perform basic daily activities. Which phenomenon best describes this clinical presentation? A) Expected natural progression of primary Alzheimer disease. B) Cholinergic crisis secondary to **donepezil** toxicity. C) Prescribing cascade resulting in central anticholinergic blockade. D) Acute vascular dementia secondary to untreated hypertension. Pause. Answer: C **Why It Is Correct**: This scenario illustrates a textbook prescribing cascade. **Donepezil** increases peripheral acetylcholine, which frequently triggers urinary incontinence. Treating that side effect with **oxybutynin**, a potent anticholinergic agent, antagonizes central M1 receptors, neutralizes the cognitive benefit of **donepezil**, and precipitates acute cognitive decline and delirium. **Why the Other Choices Are Wrong**: * **A**: A sudden, severe drop in cognitive and functional abilities over 6 weeks following a new medication is characteristic of medication-induced toxicity or delirium, not typical Alzheimer progression. * **B**: Cholinergic crisis presents with excessive salivation, lacrimation, diarrhea, bradycardia, and muscle fasciculations, which are opposite to anticholinergic blockade. * **D**: There is no acute focal neurological deficit or stroke timeline presented to suggest vascular dementia, and the temporal relationship to **oxybutynin** initiation dictates the diagnosis. **Test-Taking Pearl**: When an older adult on a cholinesterase inhibitor develops urinary incontinence, avoid anticholinergic bladder agents like **oxybutynin**; instead, evaluate for medication-induced incontinence or consider non-anticholinergic alternatives like **mirabegron**. Next Best Study Step. The single best next topic to study is **Beers Criteria and High-Risk Psychotropics in the Elderly**, focusing on renal dosing thresholds, eGFR calculation versus serum creatinine, and safe alternatives for anxiety, insomnia, and depression in older adults. Studying this topic next consolidates your understanding of deprescribing protocols and prevents common prescribing traps on national board certification exams. Next. Topic. Metabolic and Cardiac Monitoring Protocol. Source Scope Note. Chapter 17 is not present in the provided Fitzgerald workbook or lecture transcripts [1, 2]. Based strictly on the provided Fitzgerald review sources, this module covers health promotion, metabolic screening, and medication management protocols within the board-tested levels of prevention framework [3-6]. Bottom Line Summary. * **Primary prevention** prevents health problems before they occur, such as administering an **influenza vaccine** to a 66-year-old with **schizophrenia** or recommending physical activity to a 25-year-old with **major depressive disorder** [3, 7, 8]. * **Secondary prevention** detects disease in an early, preclinical, or asymptomatic state to minimize health impact, such as ordering a baseline **lipid profile** for a patient with **major depressive disorder** and a family history of **type 2 diabetes** [4, 8, 9]. * **Tertiary prevention** manages established illness to prevent target organ damage, reduce disability, and avoid complications, such as adjusting a **lithium** dosage for **bipolar disorder** or utilizing an Employee Assistance Program [4, 10, 11]. * **Safety alert**: When monitoring metabolic risk factors in patients taking psychotropics, ordering routine screening labs like a **lipid profile** or blood pressure check is classified as **secondary prevention** [4, 5, 8]. * **Board trap**: Selecting **primary prevention** or **secondary prevention** when a patient accesses post-hospitalization rehabilitation or workplace support; accessing an Employee Assistance Program after a **manic episode** is **tertiary prevention** because the condition is already established [10-12]. * **First-line**: Intervene at the lowest applicable level of prevention to maximize cost-effectiveness and optimize clinical outcomes [13-15]. Spoken Teaching on Health Promotion, Metabolic Screening, and Medication Management. * Grouping shared primary prevention facts: Immunizations like the **influenza vaccine**, environmental modifications like adequate home lighting, and health counseling regarding exercise or STI risk reduction all share the attribute of **primary prevention** because they stop pathology before it develops [3, 7, 8, 16]. * Comparing secondary and tertiary prevention distinctions: Screening procedures like a **lipid profile**, blood pressure check, mammogram, or **PHQ-9** screening represent **secondary prevention** aimed at early detection in asymptomatic states [4, 5, 8, 16]. In contrast, adjusting a **lithium** level, conducting family psychoeducation for severe mental illness, or accessing workplace rehabilitation represent **tertiary prevention** designed to manage active disease and prevent functional decline [4, 6, 10, 11]. Board-Style Practice Questions. Question 1. A 35-year-old man with **bipolar disorder** was recently hospitalized for a **manic episode**. On returning to work as an accountant in a large company, he accesses his company's Employee Assistance Program to facilitate his return to work. This is an example of which prevention strategy? - A. **Primary prevention** - B. **Secondary prevention** - C. **Tertiary prevention** - D. Anticipatory guidance Pause. Answer: C Why it is correct: Accessing an Employee Assistance Program to support workplace reintegration following hospitalization for an established **bipolar disorder** **manic episode** is **tertiary prevention** [10-12]. The goal of **tertiary prevention** is to minimize disease-induced complications and reduce long-term disability in established conditions [4, 6, 11]. Why the other choices are wrong: - A. **Primary prevention** seeks to prevent the onset of illness in healthy individuals, whereas this patient has established **bipolar disorder** [3, 5, 11]. - B. **Secondary prevention** involves screening to detect asymptomatic or preclinical disease, whereas this patient's illness is already diagnosed and treated [4, 5, 11]. - D. Anticipatory guidance is a health promotion strategy for expected developmental milestones rather than a disease prevention level [11, 12]. Question 2. In a 25-year-old patient with stable **major depressive disorder** and a strong family history of **type 2 diabetes**, checking a baseline **lipid profile** is categorized as which level of prevention? - A. **Primary prevention** - B. **Secondary prevention** - C. **Tertiary prevention** - D. Health promotion Pause. Answer: B Why it is correct: Ordering a **lipid profile** to screen for preclinical metabolic disease in an asymptomatic patient with risk factors represents **secondary prevention** [8, 9]. The objective of **secondary prevention** is early screening to identify pathology in an asymptomatic stage and minimize disease impact [4, 5]. Why the other choices are wrong: - A. **Primary prevention** consists of interventions, such as exercise counseling, performed before pathology develops [3, 5, 8]. - C. **Tertiary prevention** involves managing established pathology or adjusting psychotropic regimens [4, 6, 10]. - D. Health promotion refers to general wellness counseling rather than specific disease screening [5, 8]. Question 3. A PMHNP evaluates a 46-year-old patient with **bipolar disorder** and adjusts the therapeutic **lithium** dosage based on laboratory monitoring. Which level of prevention does this clinical action represent? - A. **Primary prevention** - B. **Secondary prevention** - C. **Tertiary prevention** - D. Disease screening Pause. Answer: C Why it is correct: Adjusting therapeutic medication levels in a patient with established **bipolar disorder** is **tertiary prevention** [10, 11, 17]. This action optimizes symptom regulation and prevents disease-induced complications or organ toxicity [4, 6]. Why the other choices are wrong: - A. **Primary prevention** prevents disease occurrence in healthy populations [3, 5]. - B. **Secondary prevention** focuses on early screening in asymptomatic individuals [4, 5]. - D. Disease screening is a component of secondary prevention rather than active medication management [4, 5]. Next Study Step. Review **Fitzgerald Chapter 14: Older Adults** to analyze age-related pharmacokinetics, polypharmacy, and neurocognitive disorder management in geriatric populations [1, 18-20]. Next. End of this drive.